Logo image of IRD

OPUS GENETICS INC (IRD) Stock Fundamental Analysis

NASDAQ:IRD - Nasdaq - US67577R1023 - Common Stock - Currency: USD

1.1  -0.01 (-0.9%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IRD. IRD was compared to 558 industry peers in the Biotechnology industry. The financial health of IRD is average, but there are quite some concerns on its profitability. IRD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IRD had negative earnings in the past year.
IRD had a negative operating cash flow in the past year.
In the past 5 years IRD reported 4 times negative net income.
IRD had negative operating cash flow in 4 of the past 5 years.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

With a Return On Assets value of -121.70%, IRD is not doing good in the industry: 80.82% of the companies in the same industry are doing better.
The Return On Equity of IRD (-245.11%) is worse than 69.71% of its industry peers.
Industry RankSector Rank
ROA -121.7%
ROE -245.11%
ROIC N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IRD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IRD has been increased compared to 1 year ago.
The number of shares outstanding for IRD has been increased compared to 5 years ago.
IRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

IRD has an Altman-Z score of -4.15. This is a bad value and indicates that IRD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.15, IRD perfoms like the industry average, outperforming 43.91% of the companies in the same industry.
IRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.15
ROIC/WACCN/A
WACC9.68%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.98 indicates that IRD should not have too much problems paying its short term obligations.
The Current ratio of IRD (1.98) is worse than 75.99% of its industry peers.
A Quick Ratio of 1.98 indicates that IRD should not have too much problems paying its short term obligations.
IRD has a Quick ratio of 1.98. This is in the lower half of the industry: IRD underperforms 74.37% of its industry peers.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.98
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

IRD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -114.29%.
IRD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.20%.
IRD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 165.10% yearly.
EPS 1Y (TTM)-114.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.24%
Revenue 1Y (TTM)-28.2%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%155.41%

3.2 Future

Based on estimates for the next years, IRD will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
The Revenue is expected to grow by 33.09% on average over the next years. This is a very strong growth
EPS Next Y22.26%
EPS Next 2Y22.89%
EPS Next 3Y13.87%
EPS Next 5Y14.87%
Revenue Next Year81.34%
Revenue Next 2Y74.98%
Revenue Next 3Y40.87%
Revenue Next 5Y33.09%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

IRD's earnings are expected to grow with 13.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.89%
EPS Next 3Y13.87%

More info and screens

0

5. Dividend

5.1 Amount

IRD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPUS GENETICS INC

NASDAQ:IRD (7/15/2025, 10:47:55 AM)

1.1

-0.01 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11
Inst Owners17.15%
Inst Owner ChangeN/A
Ins Owners5.48%
Ins Owner Change65.48%
Market Cap65.63M
Analysts80
Price Target8.67 (688.18%)
Short Float %2.44%
Short Ratio0.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.04%
Min EPS beat(2)4.95%
Max EPS beat(2)15.14%
EPS beat(4)2
Avg EPS beat(4)-4.32%
Min EPS beat(4)-20.9%
Max EPS beat(4)15.14%
EPS beat(8)3
Avg EPS beat(8)-27.66%
EPS beat(12)6
Avg EPS beat(12)-15.81%
EPS beat(16)8
Avg EPS beat(16)-13.78%
Revenue beat(2)2
Avg Revenue beat(2)40.96%
Min Revenue beat(2)39.62%
Max Revenue beat(2)42.31%
Revenue beat(4)3
Avg Revenue beat(4)23.5%
Min Revenue beat(4)-55.25%
Max Revenue beat(4)67.33%
Revenue beat(8)5
Avg Revenue beat(8)38.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.69%
EPS NY rev (1m)5.93%
EPS NY rev (3m)14.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.81
P/FCF N/A
P/OCF N/A
P/B 2.74
P/tB 2.74
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.23
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.7%
ROE -245.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.98
Altman-Z -4.15
F-Score2
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-114.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.24%
EPS Next Y22.26%
EPS Next 2Y22.89%
EPS Next 3Y13.87%
EPS Next 5Y14.87%
Revenue 1Y (TTM)-28.2%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%155.41%
Revenue Next Year81.34%
Revenue Next 2Y74.98%
Revenue Next 3Y40.87%
Revenue Next 5Y33.09%
EBIT growth 1Y-212.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-271.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-271.44%
OCF growth 3YN/A
OCF growth 5YN/A